☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC June Update

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Aripiprazole (Abilify®) has been rejected for the treatment of moderate to severe manic episodes in bipolar I disorder and for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. The review notes that efficacy data are comparisons with placebo rather than active treatments and that the economic case was not sufficiently robust.

Tadafil (Cialis®) 2.5mg and 5mg tablets have been accepted for regular once-daily administration in patients with erectile dysfunction responding to an on-demand regimen of tadalafil who anticipate frequent use (at least twice weekly).

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC June Update' by emailShare 'SMC June Update' on FacebookShare 'SMC June Update' on TwitterShare 'SMC June Update' on LinkedInShare 'SMC June Update' on reddit


No Comments to “SMC June Update”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.